HRP20170651T1 - Hpn-100 za uporabu za liječenje poremećaja retencije dušika - Google Patents
Hpn-100 za uporabu za liječenje poremećaja retencije dušika Download PDFInfo
- Publication number
- HRP20170651T1 HRP20170651T1 HRP20170651TT HRP20170651T HRP20170651T1 HR P20170651 T1 HRP20170651 T1 HR P20170651T1 HR P20170651T T HRP20170651T T HR P20170651TT HR P20170651 T HRP20170651 T HR P20170651T HR P20170651 T1 HRP20170651 T1 HR P20170651T1
- Authority
- HR
- Croatia
- Prior art keywords
- hpn
- paa
- dose
- phenylbutyrate
- glyceryl tri
- Prior art date
Links
- ZSDBFLMJVAGKOU-UHFFFAOYSA-N glycerol phenylbutyrate Chemical compound C=1C=CC=CC=1CCCC(=O)OCC(OC(=O)CCCC=1C=CC=CC=1)COC(=O)CCCC1=CC=CC=C1 ZSDBFLMJVAGKOU-UHFFFAOYSA-N 0.000 title claims 21
- 229960002815 glycerol phenylbutyrate Drugs 0.000 title claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title claims 6
- 229910052757 nitrogen Inorganic materials 0.000 title claims 3
- 230000014759 maintenance of location Effects 0.000 title 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 24
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims 12
- 229960003424 phenylacetic acid Drugs 0.000 claims 12
- 239000003279 phenylacetic acid Substances 0.000 claims 12
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims 4
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 4
- 208000030954 urea cycle disease Diseases 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000000523 end stage renal failure Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Claims (3)
1. Gliceril tri-[4-fenilbutirat] (HPN-100) naznačen time da je za uporabu u:
A) postupku liječenja poremećaja nakupljanja dušika koji su odabrani iz skupine koju čine poremećaji ciklusa uree (UCD), jetrena encefalopatija (HE) i krajnji stadij bolesti bubrega (ESRD) kod subjekta, koji sadrži:
(a) davanje prve doze gliceril tri-[4-fenilbutirata] (HPN-100),
(b) mjerenje razine feniloctene kiseline (PAA) i fenilacetilglutamina (PAGN) u plazmi,
(c) izračunavanje omjera PAA:PAGN u plazmi,
(d) određivanje da li doza gliceril tri-[4-fenilbutirata] (HPN-100) treba biti prilagođena na temelju toga da li omjer PAA:PAGN pripada u okvir ciljanog opsega od 1 do 2,5, pri čemu omjer PAA:PAGN ispod ciljanog opsega pokazuje da doza treba biti povećana i omjer PAA:PAGN iznad ciljanog opsega pokazuje da doza treba biti smanjena, i
(e) davanje druge doze gliceril tri-[4-fenilbutirata] (HPN-100) na osnovu određivanja pod (d); ili
B) postupku liječenja poremećaja nakupljanja dušika koji su odabrani iz skupine koju čine poremećaji ciklusa uree (UCD), jetrena encefalopatija (HE) i krajnji stadij bolesti bubrega (ESRD) kod subjekta kojem je prethodno davana prva doza gliceril tri-[4-fenilbutirata] (HPN-100), koji sadrži:
(a) mjerenje razine PAA i PAGN u plazmi,
(b) izračunavanje omjera PAA:PAGN u plazmi,
(c) određivanje da li prva doza gliceril tri-[4-fenilbutirata] (HPN-100) treba biti prilagođena na temelju toga da li omjer PAA:PAGN spada u okviru ciljanog opsega od 1 do 2,5, pri čemu omjer PAA:PAGN ispod ciljanog opsega pokazuje da doza treba biti povećana i omjer PAA:PAGN iznad ciljanog opsega pokazuje da doza treba biti smanjena, i
(d) davanje druge doze gliceril tri-[4-fenilbutirata] (HPN-100) na osnovu određivanja pod (d);
2. Gliceril tri-[4-fenilbutirat] (HPN-100) za uporabu prema zahtjevu 1, naznačen time da je ciljani opseg 1 do 2.
3. Gliceril tri-[4-fenilbutirat] (HPN-100) za uporabu prema zahtjevu 1, naznačen time da se mjerenje razine PAA i PAGN provodi 48 sati do 1 tjedna poslije davanja prve doze gliceril tri-[4-fenilbutirat] (HPN-100).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636256P | 2012-04-20 | 2012-04-20 | |
EP12874745.8A EP2846791B1 (en) | 2012-04-20 | 2012-09-11 | Hpn-100 for use in the treatment of nitrogen retention disorders |
PCT/US2012/054673 WO2013158145A1 (en) | 2012-04-20 | 2012-09-11 | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170651T1 true HRP20170651T1 (hr) | 2017-06-30 |
Family
ID=49380684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170651TT HRP20170651T1 (hr) | 2012-04-20 | 2017-04-27 | Hpn-100 za uporabu za liječenje poremećaja retencije dušika |
Country Status (25)
Country | Link |
---|---|
US (4) | US9561197B2 (hr) |
EP (2) | EP3222275B1 (hr) |
JP (3) | JP6234436B2 (hr) |
KR (2) | KR102264579B1 (hr) |
CN (3) | CN104540507A (hr) |
AU (3) | AU2012377389A1 (hr) |
BR (1) | BR112014026138A2 (hr) |
CL (2) | CL2014002807A1 (hr) |
CY (1) | CY1118838T1 (hr) |
DK (1) | DK2846791T3 (hr) |
EC (1) | ECSP14024561A (hr) |
ES (2) | ES2623470T3 (hr) |
HK (2) | HK1208380A1 (hr) |
HR (1) | HRP20170651T1 (hr) |
HU (1) | HUE032726T2 (hr) |
IL (2) | IL235127A (hr) |
LT (1) | LT2846791T (hr) |
MX (1) | MX365302B (hr) |
PL (1) | PL2846791T3 (hr) |
PT (1) | PT2846791T (hr) |
RS (1) | RS55870B1 (hr) |
SG (2) | SG10201608749UA (hr) |
SI (1) | SI2846791T1 (hr) |
WO (1) | WO2013158145A1 (hr) |
ZA (1) | ZA201407597B (hr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
EP3222275B1 (en) | 2012-04-20 | 2020-06-24 | Immedica Pharma AB | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
CA2891657A1 (en) * | 2012-11-21 | 2014-05-30 | Bruce Scharschmidt | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
WO2015057747A1 (en) | 2013-10-14 | 2015-04-23 | Hyperion Therapeutics, Inc. | Methods of treating urea cycle disorders |
ES2748294T3 (es) * | 2014-06-04 | 2020-03-16 | Immedica Pharma Ab | Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre |
US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
ATE201013T1 (de) | 1995-02-07 | 2001-05-15 | Brusilow Entpr Llc | Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen |
US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
EA011716B1 (ru) | 2004-11-26 | 2009-04-28 | Ю Си Эл БИЗНЕС Пи Эл Си | Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии |
US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
WO2007059031A2 (en) | 2005-11-10 | 2007-05-24 | Massachusetts Institute Of Technology | Methods and compositions for raising levels and release of gamma aminobutyric acid |
US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
CN101959429B (zh) | 2008-01-08 | 2014-09-10 | 阿克塞利亚制药公司 | 抗微生物肽***的激动剂 |
EP3133396B1 (en) | 2008-04-29 | 2018-09-05 | Horizon Therapeutics, LLC | Methods of treatment using ammonia-scavenging drugs |
HUE029912T2 (en) * | 2008-08-29 | 2017-03-28 | Horizon Therapeutics Llc | Treatments using an ammonia binding agent |
EP2338050A1 (en) * | 2008-08-29 | 2011-06-29 | Ucyclyd Pharma, Inc. | Dosing and monitoring patients on nitrogen-scavenging drugs |
WO2011011781A1 (en) | 2009-07-24 | 2011-01-27 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
EP2611470B1 (en) | 2010-08-31 | 2017-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
EP3222275B1 (en) | 2012-04-20 | 2020-06-24 | Immedica Pharma AB | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
CA2891657A1 (en) | 2012-11-21 | 2014-05-30 | Bruce Scharschmidt | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy |
-
2012
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active IP Right Grant
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active IP Right Cessation
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en active Application Filing
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2015
- 2015-09-18 HK HK15109202.8A patent/HK1208380A1/xx unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-04-27 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-03-15 HK HK18103625.7A patent/HK1243959A1/zh unknown
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170651T1 (hr) | Hpn-100 za uporabu za liječenje poremećaja retencije dušika | |
JP2014532179A5 (hr) | ||
HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
PA8812601A1 (es) | Forma de dosificacion farmaceutica solida | |
BR112013017750A2 (pt) | nanocápsulas com envoltório polimérico | |
ATE486593T1 (de) | Feste dosierungsform mit einem wirkstoff mit unterdrücktem geschmack | |
MX2014008284A (es) | Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta. | |
BR112015000203A2 (pt) | formulações de etanercept que exibem redução marcada em partículas sub-visíveis | |
SI2922576T1 (en) | Procedures for the administration and evaluation of medicines for the elimination of nitrogen for the treatment of hepatitis encephalopathy | |
MX2014008283A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. | |
HRP20231716T1 (hr) | Pripravci inhibitora dopa dekarboksilaze | |
BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
HRP20201354T1 (hr) | Tekuće formulacije levotiroksina | |
MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
BR112014006105A2 (pt) | dosagem controlada de clopidogrel com terapias para a inibição de ácido gástrico | |
PL3003285T3 (pl) | Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej | |
Peters | Characteristics of Chinese overseas foreign direct investment in Latin America (2000-2012) | |
HRP20160406T1 (hr) | Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima | |
BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
Anand et al. | T48. Antipsychotic efficacy of evenamide (NW-3509) is due to modulation of glutamatergic dysregulation | |
CL2016000880A1 (es) | Recubrimiento farmacéutico soluble en agua con estabilidad mejorada | |
NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
MX2015009077A (es) | Composicion estable que contiene fingolimod. |